Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-04-25
- Target Recruit Count
- 20
- Registration Number
- NCT05433532
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 117
- Registration Number
- NCT05431257
- Locations
- 🇩🇰
Department of Hematology, Rigshospitalet, Copenhagen, Denmark
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Faron Pharmaceuticals Ltd
- Target Recruit Count
- 181
- Registration Number
- NCT05428969
- Locations
- 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇫🇮Tampere University Hospital, Tampere, Finland
🇺🇸City of Hope National Medical Center, Duarte, California, United States
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-08-19
- Target Recruit Count
- 124
- Registration Number
- NCT05404906
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Alice Mims
- Target Recruit Count
- 125
- Registration Number
- NCT05401097
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Emory University
- Target Recruit Count
- 72
- Registration Number
- NCT05391750
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT05388006
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT05386576
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 53
- Registration Number
- NCT05379166
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 130
- Registration Number
- NCT05371054
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.